Lowers the risk of stroke and systemic embolism. ANDA 207961, held by Hetero Labs Ltd Iii. Dabigatran Etexilate Mesylate.
As of Nov 16, 2026, ANDA 207961 (Dabigatran Etexilate Mesylate), held by Hetero Labs Ltd Iii, was first approved by FDA on Aug 13, 2024, with 2 approved supplements and 0 published complete response letters.
Dabigatran etexilate capsules are direct thrombin inhibitors indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated 1.
| Aug 13, 2024 | Original application | Approved | None posted |
| May 6, 2020 | Original application | Approved |
| Dabigatran Etexilate MesylateEQ 75MG BASE · capsule;oral | Dabigatran Etexilate Mesylate | Rx |
| Dabigatran Etexilate MesylateEQ 150MG BASE · capsule;oral | Dabigatran Etexilate Mesylate | Rx |
| Dabigatran Etexilate MesylateEQ 110MG BASE · capsule;oral | Dabigatran Etexilate Mesylate | Rx |
| Jun 5, 2026 | Supplement 13Labeling · Standard review | Approved | None posted |
| Feb 24, 2025 | Supplement 11Labeling · Standard review | Approved | None posted |
| Aug 13, 2024 | Original application | Approved | None posted |
| May 6, 2020 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters